BioCentury
ARTICLE | Company News

Merck to expand cancer vaccine tech portfolio with Immune Design bid

February 22, 2019 7:20 PM UTC

Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline.

Merck will pay $5.85 per share in cash, or about $300 million. The price is a 312% premium to Immune Design's closing price of $1.42 on Feb. 20, before the deal was announced. Immune Design gained $4.40 (310%) to $5.82 on Feb. 21...